Eli Lilly slashes investment in Alzey as German health‑reform debate heats up

U.S. pharmaceutical firm Eli Lilly announced it will cut its planned investment in Alzey, Rhineland‑Palatinate by about 50 %. The project, originally slated for €2.3 billion and up to 1,000 jobs with production of three medicines, will now focus on a single drug and redirect the saved capital to sites in the United States, Canada and the United Kingdom. Lilly said the decision is driven by Germany’s forthcoming health‑insurance reform – the GKV‑Beitragsstabilisierungsgesetz – which would require higher rebates to statutory health insurers and reduce expected profits.

The cut follows a similar move by Boehringer Ingelheim, which withdrew a €900 million investment for 2027‑2030. Pharma‑industry analyst Jasmina Kirchhoff warned that these retreats constitute “clear warning shots” for Germany’s pharma location. She highlighted the lack of planning certainty caused by the proposed rebate regime and warned of a conflict between health‑policy goals and the country’s economic interests. Kirchhoff called for coordinated action among ministries to resolve the clash, noting that Germany’s health‑market decisions influence drug pricing across Europe.